Ligazid M 2.5 mg+500 mg (Tablet)

Title

• Ligazid M Tablet

Categories

• Medicine
• Diabetes Management
• Oral Hypoglycemic Preparations

Description

• Adjunct to diet and exercise for glycemic control in type 2 diabetes mellitus
• Combination of Linagliptin, a DPP-4 inhibitor, and Metformin Hydrochloride, a biguanide
• Immediate release and extended release dosage forms available
• Dosage individualized based on effectiveness and tolerability
• Cautions for renal impairment, metabolic acidosis, and hypersensitivity
• Potential interactions with cationic drugs, carbonic anhydrase inhibitors, and inducers of P-glycoprotein and CYP3A4 enzymes
• Common side effects include nasopharyngitis, diarrhea, and hypoglycemia
• Use during pregnancy and lactation only if clearly needed
• Precautions for lactic acidosis, acute pancreatitis, iodinated contrast materials, and Vitamin B12 levels
• Hypoglycemia management, alcohol consumption, other medicines, counseling, travel, emergency preparedness, and medical identification
• Overdose effects and supportive measures
• Therapeutic class of oral hypoglycemic preparations
• Storage in a cool, dry place below 30°C, protected from light and moisture

Dimensions

• Various tablet sizes available

Color Options

• Not applicable

Functions

• Improves glycemic control
• Stimulates insulin release
• Decreases glucagon secretion
• Lowers plasma glucose levels
• Increases insulin sensitivity
• Decreases hepatic glucose production
• Improves peripheral glucose uptake and utilization

Materials

• Active ingredients: Linagliptin, Metformin Hydrochloride

Technical Specifications

• Maximum recommended doses: 2.5 mg Linagliptin and 1000 mg Metformin Hydrochloride twice daily for immediate release tablets
• Maximum recommended doses: 5 mg Linagliptin and 2000 mg Metformin Hydrochloride once daily for extended release tablets
• Hemodialysis or peritoneal dialysis unlikely to remove Linagliptin but dialyzable for Metformin Hydrochloride

Design Elements

• Dosage individualization
• Immediate release and extended release formats
• Tablet formulation

Usability Features

• Cautions for renal impairment
• Recommendations for gradual dose escalation
• Individualized starting doses based on patient's current treatment
• Cautions for drug interactions and contraindications
• Management of common side effects and overdose effects
• Storage instructions

Related Brands

• Linarol-M 2.5 mg+1000 mg (Tablet) - drug-international-ltd
• Linarol-M 2.5 mg+850 mg (Tablet) - drug-international-ltd
• Linarol-M 2.5 mg+500 mg (Tablet) - drug-international-ltd
• Linatin M 2.5 mg+500 mg (Tablet) - delta-pharma-ltd
• Traneta M 2.5 mg+1000 mg (Tablet) - beximco-pharmaceuticals-ltd